FIELD: medicine, oncology, biochemistry.
SUBSTANCE: invention relates to fused proteins, namely to the multifunctional fused protein cytokine-antibody. This fused protein involves immunoglobulin region and cytokine fused protein of the formula IL-12-X or X-IL-12 wherein interleukin-12 (IL-12) represents the first cytokine and X represents the second cytokine taken among the group comprising IL-2, IL-4 and GM-CSF bound covalently either by amino-end or carboxyl-end to subunit p35 or p40 of interleukin-12 (IL-12) in its heterodimeric or a single-chain form. Indicated fused cytokine protein is fused by either its amino-end or carboxyl-end with indicated region of immunoglobulin. Multifunctional fused protein cytokine-antibody shows an anticancer activity.
EFFECT: valuable medicinal properties of protein complexes.
13 cl, 40 dwg, 18 ex
Title |
Year |
Author |
Number |
ENHANCEMENT OF IMMUNE RESPONSE WHEREIN FUSED PROTEIN ANTIBODY-CYTOKINE IS MEDIATOR BY COMBINED TREATMENT WITH AGENTS INCREASING IMMUNOCYTOKINE ABSORPTION |
2001 |
- Gilliz Stiven D.
- Lan' Jan'
- Kholden Sil'Vija A.
|
RU2272644C2 |
ENHANCEMENT OF IMMUNE RESPONSES MEDIATED BY PROTEINS FUSED FROM ANTIBODY AND CYTOKINE BY METHOD OF COMBINED ADMINISTRATION OF ANGIOGENESIS INHIBITOR |
1999 |
|
RU2229305C2 |
FUSED PROTEINS WITH IMMUNOGLOBULIN FC-FRAGMENT FOR ENHANCING IMMUNOGENICITY OF PROTEIN AND PEPTIDE ANTIGENS |
2000 |
- Dzhilliz Stefen D.
- Lo Kin Ming
- Vesolovski Dzhon S. Dzhr.
|
RU2248214C2 |
ANTI-CANCER TARGETED IMMUNOTHERAPY WITH APPLICATION OF IL-12 |
2015 |
- Shrittmatter Volfgang
- Khandgretinger Rupert
- Shilbakh-Shtyukle Karin
|
RU2689160C2 |
IL-12 COMPOSITIONS AIMED AT EDB |
2019 |
- Villa, Alessandra
- Matasci, Mattia
- Ongaro, Tiziano
|
RU2758143C1 |
HUMANISED ANTIBODY (H14,18) BASED ON MOUSE ANTIBODY 14,18, CONTACTING GD2, AND ITS FUSION WITH IL-2 |
2003 |
- Dzhilliz Stefen D.
- Lo Kin Ming
|
RU2366664C2 |
ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) |
2000 |
- Foster Donald K.
- Zu Venfeng
- Mehdden Kehren L.
- Kelli Dzhejms D.
- Spreker Sindi A.
- Brehndt Kehmeron S.
- Rikson Mark U.
- Presnell Skott R.
- Foks Brajen A.
|
RU2279441C2 |
VACCINATION USING THE ALPHA 3 DOMAIN OF MICA/B FOR CANCER TREATMENT |
2016 |
- Wucherpfennig, Kai
- Badrinath, Soumya
|
RU2747296C2 |
IMMUNOTHERAPY OF MALIGNANT DISEASES OF B-CELLS AND AUTOIMMUNE DISEASES WITH APPLICATION OF CONJUGATE AND NONCONJUGATE ANTIBODIES, COMBINATIONS OF ANTIBODIES AND CONJOINT PROTEINS |
2003 |
- Goldenberg Dehvid M.
- Khansen Khans
|
RU2335297C2 |
POLYPEPTIDE-LIGAND FLT3 (VARIANTS), POLYNUCLEOTIDE (VARIANTS), EXPRESSING VECTOR (VARIANTS), STRAIN OF CELL CHO (VARIANTS), METHOD FOR PRODUCING POLYPEPTIDE-LIGAND FLT3 (VARIANTS), PHARMACEUTICAL COMPOSITION (VARIANTS) |
1994 |
- Lajmehn Stjuart D.
- Bekmann M. Patritsija
|
RU2220979C2 |